M Camilleri1. 1. Clinical Enteric Neuroscience Translational and Epidemiological Research (C.E.N.T.E.R.), Mayo Clinic, Rochester, MN, USA.
Abstract
BACKGROUND: There have been significant advances in understanding the pathophysiological mechanisms in patients with neurogastroenterological disorders including irritable bowel syndrome (IBS) and functional abdominal pain, functional diarrhea, chronic constipation, gastroparesis, and functional dyspepsia. These advances have led to the development of novel pharmacological therapy of neurogastroenterological disorders. PURPOSE: To review peer-reviewed articles or prominent preliminary communications presented in the past year regarding medications in development for functional gastrointestinal disorders or gastroparesis. The medications fall into two main categories: first, established classes of medications within established classes, such as 5-HT3 receptor antagonists and 5-HT4 receptor agonists, and second, new classes of medications such as a combined μ-opioid agonist and δ-antagonist, or a small molecule ghrelin agonist.
BACKGROUND: There have been significant advances in understanding the pathophysiological mechanisms in patients with neurogastroenterological disorders including irritable bowel syndrome (IBS) and functional abdominal pain, functional diarrhea, chronic constipation, gastroparesis, and functional dyspepsia. These advances have led to the development of novel pharmacological therapy of neurogastroenterological disorders. PURPOSE: To review peer-reviewed articles or prominent preliminary communications presented in the past year regarding medications in development for functional gastrointestinal disorders or gastroparesis. The medications fall into two main categories: first, established classes of medications within established classes, such as 5-HT3 receptor antagonists and 5-HT4 receptor agonists, and second, new classes of medications such as a combined μ-opioid agonist and δ-antagonist, or a small molecule ghrelin agonist.
Authors: Won Sohn; Oh Young Lee; Sang Pyo Lee; Kang Nyeong Lee; Dae Won Jun; Hang Lak Lee; Byung Chul Yoon; Ho Soon Choi; Jongmin Sim; Ki-Seok Jang Journal: Scand J Gastroenterol Date: 2013-11-21 Impact factor: 2.423
Authors: D Keszthelyi; F J Troost; D M Jonkers; Z Helyes; H M Hamer; S Ludidi; S Vanhoutvin; K Venema; J Dekker; J Szolcsányi; A A Masclee Journal: Eur J Pain Date: 2013-03-25 Impact factor: 3.931
Authors: L A Houghton; F Cremonini; M Camilleri; I Busciglio; C Fell; V Cox; D H Alpers; O E Dewit; G E Dukes; E Gray; R Lea; A R Zinsmeister; P J Whorwell Journal: Neurogastroenterol Motil Date: 2007-09 Impact factor: 3.598
Authors: Scott R Armstrong; Christina B Campbell; Carrie L Richardson; Ross G Vickery; Pamela R Tsuruda; Daniel D Long; Sharath S Hegde; David T Beattie Journal: Naunyn Schmiedebergs Arch Pharmacol Date: 2013-03-13 Impact factor: 3.000
Authors: F Cremonini; J P Nicandro; V Atkinson; R Shringarpure; E Chuang; A Lembo Journal: Aliment Pharmacol Ther Date: 2012-07-10 Impact factor: 8.171
Authors: Andrea Shin; Michael Camilleri; Irene Busciglio; Duane Burton; Elizabeth Stoner; Patrick Noonan; Keith Gottesdiener; Steven A Smith; Adrian Vella; Alan R Zinsmeister Journal: Diabetes Care Date: 2012-09-06 Impact factor: 19.112